Benzinga | Jun 16, 2021 04:03PM EDT

Collegium Pharma Highlights Publication Of 'Nonmedical Use of Xtampza ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment' In Journal Of Pain Research

Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza(r) ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index -- Multimedia Version (ASI-MV(r))," was published in the peer-reviewed medical journal, Journal of Pain Research.

"An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain."

While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse. Please see full Prescribing Information for Xtampza ER including Boxed Warning on addiction, abuse, and misuse and other serious risks.

The publication can be found here: link